Does Kaiser Permanente Cover Repatha (Evolocumab)?

What Is Repatha and Why Does Coverage Complexity Matter?

Repatha (evolocumab) is a fully human monoclonal antibody that inhibits PCSK9, a protein that degrades LDL receptors on liver cells. By blocking PCSK9, evolocumab increases the number of functional LDL receptors, which lowers circulating LDL-C by 50 to 60 percent on top of background statin therapy [1]. The FDA approved evolocumab in August 2015 for adults with heterozygous familial hypercholesterolemia (HeFH), homozygous familial hypercholesterolemia (HoFH), and established atherosclerotic cardiovascular disease (ASCVD) who require additional LDL lowering [2].

The drug's monthly list price sits near $580, making insurer approval the single largest barrier most patients face. Kaiser Permanente operates an integrated HMO model with a closed formulary, which means its coverage decisions flow through internal clinical pharmacy committees rather than a standard pharmacy benefit manager. That structure gives Kaiser more direct control over specialty drug access, and PCSK9 inhibitors are among the most tightly managed categories on its formulary.

Understanding the approval pathway before the prescriber submits paperwork reduces denial rates and shortens the time to first injection.

Does Kaiser Permanente's Formulary Include Repatha?

Repatha sits on Kaiser Permanente's closed formulary as a non-preferred specialty agent, meaning coverage exists but is not granted without prior authorization. Kaiser's pharmacy and therapeutics (P&T) committee reviews PCSK9 inhibitors against the ACC/AHA 2018 cholesterol guideline framework, which states: "For patients with clinical ASCVD and LDL-C 70 mg/dL or higher on maximally tolerated statin therapy, it is reasonable to add ezetimibe" and, if LDL-C remains elevated, to add a PCSK9 inhibitor [3].

Because Kaiser is an integrated system, the prescriber must be a Kaiser-employed physician or, in some regions, a Kaiser-contracted cardiologist or lipid specialist. Outside providers cannot initiate a Kaiser Repatha PA directly. This internal-only pathway is the feature most likely to catch members off guard, especially those who received a Repatha recommendation from a non-Kaiser specialist.

Formulary tier placement directly controls the member's out-of-pocket cost. On most Kaiser commercial plans, specialty non-preferred drugs carry coinsurance of 20 to 30 percent after the deductible, which can mean $116 to $174 per month even after approval.

What Are Kaiser Permanente's Prior Authorization Criteria for Repatha?

Kaiser Permanente's PA criteria for evolocumab align closely with published cardiovascular guidelines, but require specific documentation at submission. The prescriber must demonstrate [3, 4]:

Diagnosis confirmation. The member has a confirmed diagnosis of HeFH, HoFH, or established ASCVD (prior MI, stroke, or symptomatic peripheral artery disease). For FH, documentation should reference the Dutch Lipid Clinic Network score or a genetic test result where available.

Maximally tolerated statin therapy. The member has been on the highest dose of a statin they can tolerate for at least 4 to 12 weeks (Kaiser's internal policy specifies 8 weeks in most regions). High-intensity statins per the ACC/AHA guideline mean atorvastatin 40 to 80 mg or rosuvastatin 20 to 40 mg daily [3].

Ezetimibe add-on. The member has also completed a documented trial of ezetimibe 10 mg daily for at least 4 weeks. Ezetimibe lowers LDL-C by an additional 18 to 25 percent and is generic, which is why payers require it before approving a $580-per-month biologic [5].

Residual LDL-C threshold. After statin plus ezetimibe, the member's fasting LDL-C remains at or above 70 mg/dL for ASCVD, or at or above 100 mg/dL for FH without clinical ASCVD. Some Kaiser regions use a more conservative threshold of LDL-C at or above 100 mg/dL for secondary prevention; confirm the specific regional threshold with the pharmacy team before submitting.

Statin intolerance documentation. If the member cannot tolerate a statin, the prescriber must document at least two separate statin trials at any dose, with the adverse effect (typically myalgia with CK elevation or rhabdomyolysis) recorded in the chart. Intolerance claims without lab correlation are a common reason for first-pass denial.

The FOURIER trial, published in the New England Journal of Medicine in 2017 (N=27,564), provides the core efficacy evidence Kaiser's P&T committee relies on. Evolocumab reduced LDL-C by 59 percent from baseline and cut the composite primary endpoint of cardiovascular death, MI, stroke, hospitalization for unstable angina, or coronary revascularization from 11.3 percent (placebo) to 9.8 percent (evolocumab) over a median 2.2 years, a 15 percent relative risk reduction (HR 0.85; 95% CI 0.79 to 0.92; P<0.001) [1].

That absolute risk reduction of 1.5 percentage points over 2.2 years, translating to a number needed to treat of approximately 67, is the statistic most likely to appear in a Kaiser P&T review when the committee debates whether the drug's cost is justified for a given patient's baseline risk.

Does Kaiser Require Step Therapy Before Approving Repatha?

Yes. Kaiser Permanente requires documented step therapy before approving evolocumab. Step therapy means the member must try and fail (or document intolerance to) less expensive options in sequence before the payer will cover the more expensive drug [6].

For Repatha, Kaiser's step therapy sequence is:

1. High-intensity statin (atorvastatin 40 to 80 mg or rosuvastatin 20 to 40 mg) for at least 8 weeks
2. Addition of ezetimibe 10 mg for at least 4 additional weeks
3. LDL-C reassessment confirming residual elevation above the threshold
4. PA request with complete documentation of steps 1 through 3

Members who already completed these steps with a non-Kaiser provider should request chart records before the first Kaiser appointment. Kaiser's internal electronic health record cannot pull outside lab values automatically, and missing step-therapy documentation is the second most common reason for first-pass PA denial.

Some Kaiser regions also accept bempedoic acid (Nexletol) as an intermediate step between ezetimibe and a PCSK9 inhibitor for statin-intolerant patients, reflecting the 2023 ACC Expert Consensus Decision Pathway update [4]. Confirm whether this applies to the member's specific regional plan.

How to Appeal a Kaiser Permanente Denial of Repatha

A denied PA is not the end of the road. Kaiser's multi-level appeal pathway gives members and prescribers several opportunities to overturn a denial [7].

Level 1: Internal appeal to Kaiser Member Services. File within 60 days of the denial notice. The prescriber should submit a peer-to-peer review request simultaneously. In many cases, a 15-minute call between the prescribing cardiologist and the Kaiser medical reviewer resolves disagreements that denial letters cannot. Include the FOURIER trial data [1], the member's specific LDL-C values, and the step-therapy documentation.

Level 2: Kaiser Grievance and Appeals department. If Level 1 fails, a formal written grievance escalates the case to a different medical reviewer. This review must be completed within 30 days for standard appeals or 72 hours for expedited urgent appeals when the member's health is at risk.

Level 3: State Independent Review Organization (IRO). Every state in which Kaiser operates has a designated IRO. An IRO is an independent medical panel not employed by Kaiser that reviews denied appeals and can overturn Kaiser's decision. IRO decisions are legally binding. For California Kaiser members, the IRO is administered through the California Department of Managed Health Care. Nationally, the process follows ACA external review standards established under 45 CFR Part 147 [8].

The prescriber's letter matters enormously. A letter that quotes the 2018 ACC/AHA guideline Class IIa recommendation for PCSK9 inhibitors in very high-risk ASCVD patients [3], cites the member's specific 10-year ASCVD risk score, and includes FOURIER outcome data has a measurably higher approval rate at the IRO stage than letters that simply state "medically necessary."

Urgent or expedited appeals. If the member has experienced a recent acute coronary syndrome or MI within 3 months, request expedited review. Under federal law, urgent appeals must be reviewed within 72 hours [8].

Repatha Dosing and Administration Approved by the FDA

The FDA-approved dosing for evolocumab depends on indication [2]:

• HeFH or established ASCVD: 140 mg subcutaneously every 2 weeks, or 420 mg subcutaneously once monthly via the on-body infusor
• HoFH: 420 mg subcutaneously once monthly

Evolocumab is supplied as a single-dose prefilled autoinjector (SureClick) at 140 mg/mL, or as three 140 mg/mL prefilled syringes for the 420 mg dose. Storage is at 36°F to 77°F (2°C to 25°C); the patient may keep the autoinjector at room temperature for up to 30 days before use [2].

Injection sites are the abdomen, thigh, or upper arm. The drug does not require dose adjustment for renal impairment or moderate hepatic impairment. No drug-drug interactions have been identified that require dose modification, consistent with the drug's non-CYP450 clearance pathway [2, 9].

Safety Profile of Evolocumab: What the Trials Show

Evolocumab's safety record across the FOURIER trial (N=27,564, median 2.2 years) and the open-label OSLER-1 and OSLER-2 extension studies (N=4,465 to 12 months) is reassuring [1, 10]. Adverse events occurring more frequently with evolocumab than placebo in FOURIER included nasopharyngitis (10.5% vs. 10.2%), upper respiratory tract infection (9.3% vs. 8.8%), and injection-site reactions (2.1% vs. 1.6%). Neurocognitive adverse events, which received attention early in PCSK9 inhibitor development, were not significantly different between evolocumab and placebo in FOURIER [1].

The EBBINGHAUS trial, a pre-specified cognitive substudy of FOURIER (N=1,204), used the Cambridge Neuropsychological Test Automated Battery and found no difference in executive function, memory, or psychomotor speed between evolocumab and placebo at 19 months [11]. That result was important for FDA label discussions because early mechanistic concern existed about whether very low LDL-C levels (some participants reached LDL-C below 25 mg/dL) would impair neuronal membrane function.

New-onset diabetes was not increased with evolocumab relative to placebo in FOURIER, in contrast to the modest diabetes signal seen with statins. Muscle-related adverse events were comparable between groups [1].

Can Kaiser Permanente Members Use the Amgen Repatha Savings Card?

The Amgen Copay Card for Repatha can reduce out-of-pocket costs to as low as $5 per month for eligible commercially insured patients. The key eligibility restriction is that the card cannot be used by patients enrolled in a federal or state government-funded insurance program, including Medicare Part D, Medicaid, TRICARE, or the VA [12].

Kaiser Permanente commercial plans (employer-sponsored or individual market) are eligible for the Amgen savings card. Kaiser Medicare Advantage plans are not eligible because Medicare Advantage is a federal program.

Members should confirm their plan type before applying. The easiest check: look at the insurance card. If it states "Medicare Advantage" or "Medi-Cal" (California Medicaid), the copay card cannot be used. If it states an employer group name or is purchased through Covered California, the card likely applies.

Amgen also operates the Amgen Safety Net Foundation for uninsured or underinsured patients, which provides Repatha free of charge to qualifying individuals with household income at or below 500 percent of the federal poverty level [12]. Eligibility and application materials are available directly from Amgen.

How Evolocumab Compares to Other LDL-Lowering Therapies

Clinicians managing patients through Kaiser's step therapy must understand the relative LDL-C reduction achievable at each step before Repatha becomes the appropriate next choice [3, 5, 13]:

• Atorvastatin 80 mg: approximately 50 percent LDL-C reduction
• Rosuvastatin 40 mg: approximately 55 percent LDL-C reduction
• Adding ezetimibe 10 mg to high-intensity statin: additional 18 to 25 percent reduction
• Adding evolocumab to statin plus ezetimibe: additional 50 to 60 percent reduction on top of background therapy
• Inclisiran (Leqvio), a siRNA PCSK9 inhibitor: similar LDL-C reduction (50 percent) with twice-yearly dosing; FDA-approved December 2021 [13]

For patients with HoFH, where LDL receptor activity is severely impaired, evolocumab still reduces LDL-C by approximately 30 percent, reflecting its partial mechanism through LDL receptor-independent pathways. This compares favorably with lomitapide and mipomersen, which carry black box warnings for hepatotoxicity and are reserved for HoFH patients who cannot achieve goals with receptor-dependent agents [2, 14].

The ACC's 2022 Expert Consensus Decision Pathway on PCSK9 inhibitors identifies very high-risk ASCVD patients, defined as those with two or more major ASCVD events or one major event plus multiple high-risk conditions, as the group most likely to derive net clinical benefit sufficient to justify PCSK9 inhibitor cost [4]. Kaiser's internal PA criteria largely mirror this risk stratification.

What Happens If Kaiser Denies Repatha and the Appeal Fails?

If the IRO upholds Kaiser's denial, members have additional options. They may request a formulary exception by submitting new clinical evidence if the member's circumstances change (for example, a second MI occurs after the initial denial). State insurance commissioner complaints are available if the denial is believed to violate state-mandated coverage requirements. Several states, including California, have enacted step-therapy override laws requiring that step therapy be waived when a prescriber documents that a required step-therapy drug was previously ineffective or caused harm [15].

Patients who exhaust all appeal options may consider Amgen's Safety Net Foundation for free drug, or cash-pay via specialty pharmacy at list price ($580/month), partially offset by manufacturer patient assistance.

Original HealthRX Clinical Decision Summary

The following framework consolidates Kaiser Permanente's Repatha approval pathway into a sequential decision tool for prescribers:

Step 1. Confirm the member's Kaiser plan type (commercial vs. Medicare Advantage) before initiating any PA. Medicare Advantage members face different formulary and appeal structures.

Step 2. Document the diagnosis with objective criteria: Dutch Lipid Clinic Network score of 6 or higher for FH, or a qualifying ASCVD event in the chart.

Step 3. Record 8 weeks of high-intensity statin therapy with fasting LDL-C labs at baseline and at the end of the trial period.

Step 4. Add and document 4 weeks of ezetimibe 10 mg with a follow-up fasting lipid panel.

Step 5. Calculate the member's 10-year ASCVD risk score using the ACC/AHA Pooled Cohort Equations and include it in the PA narrative.

Step 6. Quote the 2018 ACC/AHA guideline Class IIa recommendation and the FOURIER HR of 0.85 (P<0.001) in the clinical justification section [1, 3].

Step 7. Request peer-to-peer review within 48 hours of any denial before filing a formal written appeal.

Step 8. If an expedited appeal is indicated by acute clinical circumstances, explicitly state the urgency in writing and request 72-hour review.

This eight-step sequence, used consistently at HealthRX partner practices, reduces first-pass PA denial rates and positions Level 3 IRO submissions with the strongest possible clinical record.